Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC

Clinical trial NCT05516589 · COMPLETED

Trial details

NCT number: NCT05516589
Sponsor: West China Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma

Start date: 2022-09-12
Primary completion: 2023-10-29
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.